Drugs / BG505
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05471076 | Aug 2022 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05471076 ↗ |
| Modality | Protein / enzyme biologic | “trimeric HIV-1 envelope glycoprotein gp140” NCT05471076 ↗ |